Results 11 to 20 of about 389,148 (301)

Modulating T Cell Responses by Targeting CD3

Cancers, 2023
Simple Summary CD3 complex provides the first signal sensed by the TCR of the lymphocyte to trigger its activation. Thus, it becomes a very attractive receptor to determine the fate of the immune response in different contexts from tolerance induction to
Moreno, B. (Beatriz), Villanueva-Ruiz, M.E. (María Elena), van-Santen, H.M. (Hisse M.), Meraviglia-Crivelli, D. (Daniel), Zheleva, A. (Angelina), Pastor, F. (Fernando), Barainka, M. (Martin), Menon, A.P. (Ashwathi Puravankara), Nonatelli, F. (Francesca)   +8 more
core   +3 more sources

TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy [PDF]

JCI Insight, 2018
T cells engineered to express chimeric antigen receptors (CARs) against B cell antigens are being investigated as cellular immunotherapies. Similar approaches designed to target T cell malignancies have been hampered by the critical issue of T-on-T ...
Georgiadis, C, Preece, R, Mock, U, Qasim, W, Rasaiyaah, J   +4 more
core   +3 more sources

CD3+ Macrophages Deliver Proinflammatory Cytokines by a CD3- and Transmembrane TNF-Dependent Pathway and Are Increased at the BCG-Infection Site

Frontiers in Immunology, 2019
Macrophages are essential cells of the innate immune response against microbial infections, and they have the ability to adapt under both pro- and anti-inflammatory conditions and develop different functions.
Adriana Rodriguez-Cruz, Dominique Vesin, Lucero Ramon-Luing, Joaquin Zuñiga, Valérie F. J. Quesniaux, Bernhard Ryffel, Ricardo Lascurain, Ricardo Lascurain, Irene Garcia, Leslie Chávez-Galán   +9 more
doaj   +2 more sources

Cinasas intracelulares y señalización mediada por CD5 [PDF]

, 2001
[spa] El receptor linfocitario CD5 es una glicoproteína monomérica de membrana de 67KDa. Funcionalmente, es una molécula accesoria, implicada en la modulación de los procesos de activación y diferenciación mediados por el receptor antigénico en células T
Vilà de las Heras, Josep M.
core   +7 more sources

Cholesterol inhibits TCR signaling by directly restricting TCR-CD3 core tunnel motility.

Molecules and Cells, 2022
Cholesterol molecules specifically bind to the resting αβTCR to inhibit cytoplasmic CD3ζ ITAM phosphorylation through sequestering the TCR-CD3 complex in an inactive conformation.
Yan Chen, Yuwei Zhu, Xiang Li, Wenbo Gao, Ziqi Zhen, D. Dong, Buliao Huang, Zhuo Ma, Anqi Zhang, Xiao-Jing Song, Yan Ma, Changyou Guo, Fan Zhang, Zhiwei Huang   +13 more
semanticscholar   +1 more source

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Cancers, 2021
Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells.
J. Middelburg, K. Kemper, P. Engelberts, A. Labrijn, J. Schuurman, T. van Hall   +5 more
semanticscholar   +1 more source

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Scientific Reports, 2021
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumor cells.
Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford, D. DiLillo, Richard Tavaré, E. Ullman, Shu Mao, Lauren Canova, Olga O Sineshchekova, Jennifer Finney, Arpita Pawashe, Supriya R. Patel, Ryan Mckay, Sahar Rizvi, Ermelinda Damko, D. Chiu, Kristin Vazzana, Priyanka Ram, Katja Mohrs, Amanda D’Orvilliers, Jenny Xiao, S. Makonnen, Carlos Hickey, C. Arnold, Jason T Giurleo, Ya-Ping Chen, Courtney Thwaites, Drew Dudgeon, Kevin Bray, A. Rafique, Tammy Huang, F. Delfino, Aynur Hermann, J. Kirshner, M. Retter, R. Babb, D. MacDonald, Gang Chen, W. Olson, G. Thurston, S. Davis, J. Lin, Eric J. Smith   +43 more
semanticscholar   +1 more source

Overcoming the challenges associated with CD3+ T-cell redirection in cancer

British Journal of Cancer, 2021
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to tumours is a promising immunotherapeutic strategy for the treatment of haematological malignancies and solid cancers.
Ajit Singh, Sundee Dees, I. Grewal
semanticscholar   +1 more source

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity

, 2022
INTRODUCTION: Systemic lupus erythematosus (SLE) patients have decreased natural killer (NK) cell counts. The decrease in the number of NK cells has implications for a decrease in the function of NK cells which can affect the progression of SLE disease ...
Dwi Soelistyoningsih, Handono Kalim, Susianti, Hani, Kalim, Handono, Handono, Kusworini, Soelistyoningsih, Dwi, Hani Susianti, Kusworini Handono   +7 more
core   +1 more source

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.

JCI Insight, 2020
Systemic cytokine release and on-target/off-tumor toxicity to normal tissues are the main adverse effects limiting the clinical utility of T cell-redirecting therapies.
K. Staflin, Christina L. Zuch de Zafra, L. Schutt, Vanessa L. Clark, Fiona Zhong, Maria Hristopoulos, Robyn Clark, Ji Li, M. Mathieu, Xiaocheng Chen, Jennifer Johnston, Justin Low, R. Ybarra, Dionysos Slaga, Ji-Hong Yang, Meric A. Ovacik, N. Dybdal, K. Totpal, M. Junttila, Diego A. Ellerman, Genee Y. Lee, M. Dennis, R. Prell, T. Junttila   +23 more
semanticscholar   +1 more source